Rezolute, Inc. (RZLT)
4.25
+0.03
(+0.71%)
USD |
NASDAQ |
Sep 14, 12:52
Rezolute Enterprise Value : 287.20M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 287.20M |
| September 10, 2026 | 282.38M |
| September 09, 2026 | 271.79M |
| September 08, 2026 | 304.53M |
| September 04, 2026 | 321.86M |
| September 03, 2026 | 318.01M |
| September 02, 2026 | 319.94M |
| September 01, 2026 | 314.16M |
| August 31, 2026 | 332.45M |
| August 28, 2026 | 325.71M |
| August 27, 2026 | 360.38M |
| August 26, 2026 | 366.16M |
| August 25, 2026 | 363.27M |
| August 24, 2026 | 363.27M |
| August 21, 2026 | 370.97M |
| August 20, 2026 | 329.57M |
| August 19, 2026 | 335.34M |
| August 18, 2026 | 329.57M |
| August 17, 2026 | 331.49M |
| August 14, 2026 | 323.79M |
| August 13, 2026 | 323.79M |
| August 12, 2026 | 333.42M |
| August 11, 2026 | 325.71M |
| August 10, 2026 | 331.49M |
| August 07, 2026 | 332.45M |
| Date | Value |
|---|---|
| August 06, 2026 | 333.42M |
| August 05, 2026 | 331.49M |
| August 04, 2026 | 359.42M |
| August 03, 2026 | 353.64M |
| July 31, 2026 | 335.34M |
| July 30, 2026 | 350.75M |
| July 29, 2026 | 333.42M |
| July 28, 2026 | 354.60M |
| July 27, 2026 | 356.53M |
| July 24, 2026 | 361.34M |
| July 23, 2026 | 392.16M |
| July 22, 2026 | 362.30M |
| July 21, 2026 | 370.97M |
| July 20, 2026 | 309.34M |
| July 17, 2026 | 324.75M |
| July 16, 2026 | 301.64M |
| July 15, 2026 | 337.27M |
| July 14, 2026 | 345.93M |
| July 13, 2026 | 337.27M |
| July 10, 2026 | 338.23M |
| July 09, 2026 | 374.82M |
| July 08, 2026 | 358.45M |
| July 07, 2026 | 359.42M |
| July 06, 2026 | 355.56M |
| July 02, 2026 | 353.64M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| SELLAS Life Sciences Group, Inc. | 2.193B |
| AbbVie, Inc. | 518.65B |
| Marker Therapeutics, Inc. | 7.252M |
| Avalo Therapeutics, Inc. | 454.68M |
| Krystal Biotech, Inc. | 9.433B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -16.17M |
| Total Expenses (Quarterly) | 16.17M |
| EPS Diluted (Quarterly) | -0.1554 |
| Earnings Yield | -19.04% |
| Normalized Earnings Yield | -19.04 |